Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling

Cell Death and Differentiation

Volumn 8, Issue 11, 2001, Pages 1066-1075

  El Deiry, W S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Cancer therapy; KILLER DR5; p53; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; FAS ANTIGEN; PROTEIN P21; PROTEIN P53; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE G1 PHASE; CELL DEATH; CYTOPLASM; DRUG DESIGN; EFFECTOR CELL; HUMAN; HUMAN CELL; MITOCHONDRION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DRUG DESIGN; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035156737     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400943     Document Type: Review

References (105)

1. Surfing the p53 network
2. Genetic analysis of chemoresistance in primary murine lymphomas
3. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
4. Pharmacological rescue of mutant p53 conformation and function
5. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
6. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53
7. Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides
8. Death receptors: Signaling and modulation
9. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death
10. Molecular determinants of response to TRAIL in killing of normal and cancer cells
11. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines
12. p53: Death star
13. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
14. The many substrates and functions of ATM
15. Mouse models in tumor suppression
16. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin
17. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice
18. Rescue of embryonic lethality in MDM2-deficient mice by absence of p53
19. Partial rescue of Brca1(5-6) early embryonic lethality by p53 or p21 null mutation
20. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis
21. Wild-type p53 restores cell-cycle control and inhibits gene amplification in cells with mutant p53 alleles
22. Altered cell-cycle arrest and gene amplification potential accompanies loss of wild-type p53
23. Genomic instability in Gadd45a-deficient mice
24. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia
25. Suppression of human colorectal carcinoma cell growth by wild-type p53
26. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells
27. p53 status and the efficacy of cancer therapy in-vivo
28. p53 is required for radiation-induced apoptosis in mouse thymocytes
29. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
30. An information-intensive approach to the molecular pharmacology of cancer
31. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
32. Cell-cycle arrest versus cell death in cancer therapy
33. p53 and chemosensitivity
34. Regulation and function of the p53 tumor suppressor protein
35. The ARF/p53 pathway
36. Regulation of p53 downstream genes
37. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
38. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
39. The MDM2 RING-finger domain is required to promote p53 nuclear export
40. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells
41. p53-independent functions of the p19(ARF) tumor suppressor
42. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation
43. ATM and ATR: Networking cellular responses to DNA damage
44. ATR disruption leads to chromosomal fragmentation and early embryonic lethality
45. p53 accumulates but is functionally impaired when DNA synthesis is blocked
46. DNA replication blockade impairs p53-transactivation
47. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines
48. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins
49. DNA damage activates p53 through a phosphorylation-acetylation cascade
50. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by ser-46-phosphorylated p53
51. Crystal structure of a p53 tumor-suppressor DNA complex - Understanding tumorigenic mutations
52. The p53 gene family
53. AIS is an oncogene amplified in squamous cell carcinoma
54. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
55. Role for the p53 homologue p73 in E2F-1-induced apoptosis
56. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53
57. Drosophila p53 binds a damage response element at the reaper locus
58. p73 beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells
59. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage
60. A transactivation-deficient mouse model provides insights into Trp53 regulation and function
61. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
62. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
63. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays
64. Noxa, a BH3-only member of the Bc1-2 family and candidate mediator of p53-induced apoptosis
65. PUMA induces rapid apoptosis of colorectal cancer cells
66. PUMA, a novel proapoptotic gene, is induced by p53
67. The combined functions of proapoptotic Bc1-2 family members Bak and Bax are essential for normal development of multiple tissues
68. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis
69. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
70. The potential of TRAIL for cancer chemotherapy
71. Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells
72. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin
73. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo
74. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
75. The biochemistry of apoptosis
76. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand
77. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo
78. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32 beta
79. Bax-deficient mice with lymphoid hyperplasia and male germ-cell death
80. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons
81. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death
82. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling
83. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice
84. p53 is essential for chemotherapy-induced hair loss
85. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
86. On the TRAIL from p53 to apoptosis?
87. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site
88. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor
89. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
90. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
91. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance
92. Rare loss-of-function mutation of a death receptor gene in head and neck cancer
93. Alterations of the DR5/TRAIL receptor 23 gene in non-small cell lung cancers
94. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL R2) genes in metastatic breast cancers
95. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
96. p53-Independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma
97. Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer
98. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo
99. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of Simvastatin and TRAIL
100. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
101. Steering anti-cancer drugs away from the TRAIL
102. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
103. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells, and can stabilize wild-type p53 protein
104. Novel strategies for therapeutic design in molecular oncology using gene expression profiles